Indications
Treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor-VIII deficiency). ReFacto AF is appropriate for use in adults and children of all ages, including newborns. ReFacto AF does not contain von-Willebrand factor, and hence is not indicated in von-Willebrand's disease.
Composition
- Active substance
- moroctocog alfa
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- ReFacto AF
- Active substance
- moroctocog alfa
- ATC code
- B02BD02
- Therapeutic area
- Hemophilia A
- Marketing authorisation holder
- Pfizer Europe MA EEIG